Kymera Therapeutics Inc

KYMR is in Stage 3 distribution with active lower highs & lower lows pattern, confirming medium-term bearish bias. Short-term weakness at EMAs favors selling into rallies with price below declining 9/20 EMAs and 50 SMA, but long-term trend remains supported by the 200-day SMA. We will sell now into resistance around the 20-day EMA and prior swing highs.

• ↑Q2 collaboration revenue $65M, beating $32.8M estimate driven by Gilead and Sanofi milestones
• ↑KT-621 Phase 2b atopic dermatitis enrollment completed six months early; top-line data by year-end 2026
• ↓Negative profitability and earnings yield highlight inefficient capital returns